Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). The preclinical profile of TR-701 has been documented in a series of presentations at the recent ICAAC conference and can be accessed at the Trius website. Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
(Date:12/8/2016)... PUNE, India , December 8, 2016 According ... (Diagnostic (Heart, Pulse, BP, Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, ... to 2021", published by MarketsandMarkets, the global market, in terms of value, ... in 2016, at a CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... 8, 2016  Haemonetics Corporation (NYSE: HAE ) ... System), an innovative software suite designed to help customers drive ... launch of NextGen DMS 4 improves core features and introduces ... per liter of plasma collected, enhancing quality and regulatory compliance ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... TX (PRWEB) , ... December 08, 2016 , ... STAT ... continue to be a convenient service for Texas, they are expanding their presence in ... involve a hiring spree that will bring new jobs to the Dallas and Forth ...
(Date:12/8/2016)... Francisco, California (PRWEB) , ... December 08, 2016 , ... ... coaches, has raised an $18M Series B led by Canvas Ventures . Other ... the capital to scale its mobile platform to serve more consumers who are managing ...
(Date:12/8/2016)... ... 08, 2016 , ... Peter Zipp Insurance, an Arizona-based insurance ... greater Phoenix metropolitan region, is announcing a charity event to provide support and ... Youth Connection is to promote community awareness of the ongoing needs of at-risk ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... services to families and business owners in and around central Kansas, is joining ... to at-risk youth in the region. , Headquartered in Wichita, Youth Horizons works ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
Breaking Medicine News(10 mins):